Inventor · disambiguated record
Shweta Singh
Also filed as: SINGH SHWETA
19 granted patents·14 pending applications·263 citations·filing 2011–2024
95Inventor score
Files withCYTOMX THERAPEUTICS INC12TAKEDA PHARMACEUTICALS CO9ABBVIE INC3COMPUGEN LTD2COJOCARU GADY S1
Top patents by PatentIndex Score
33 records- 0198US10179817B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 15, 2019·36 cites·58 claims
- 0298US8362211B2Anti-CD38 antibodiesTAKEDA PHARMACEUTICAL·Filed 2011·Granted Jan 29, 2013·71 cites·12 claims
- 0397US11414496B2Anti-CD38 binding domainsMILLENNIUM PHARM INC·Filed 2020·Granted Aug 16, 2022·4 cites·21 claims
- 0497US10745481B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·22 cites·88 claims
- 0595US11753466B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·7 cites·64 claims
- 0695US10233244B2Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Mar 19, 2019·26 cites·48 claims
- 0795US9676869B2Conjugated anti-CD38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Jun 13, 2017·12 cites·20 claims
- 0894US11267896B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Mar 8, 2022·10 cites·34 claims
- 0994US10494444B2Anti-CD38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Dec 3, 2019·8 cites·10 claims
- 1094US10336833B2Conjugated anti-CD38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Jul 2, 2019·9 cites·30 claims
- 1194US9517276B2Compositions and methods for conjugating activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2014·Granted Dec 13, 2016·24 cites·31 claims
- 1293US2025171561A1Anti-cd38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 1390US9790285B2Anti-CD38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2014·Granted Oct 17, 2017·7 cites·24 claims
- 1490US9102744B2Conjugated anti-CD38 antibodiesELIAS KATHLEEN ANN·Filed 2011·Granted Aug 11, 2015·13 cites·17 claims
- 1585US12209138B2Anti-CD38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Jan 28, 2025·0 cites·17 claims
- 1685US2025099606A1Compositions and methods for conjugating activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1784US9617336B2C10RF32 antibodies, and uses thereof for treatment of cancerCOMPUGEN LTD·Filed 2013·Granted Apr 11, 2017·14 cites·23 claims
- 1878US11434304B2Anti-CD38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Sep 6, 2022·0 cites·28 claims
- 1978US2024076374A1Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2076US12312411B2Anti-CD38 binding domainsTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted May 27, 2025·0 cites·20 claims
- 2176US2024115724A1Anti-cd71 activatable antibody drug conjugates and methods of use thereofABBVIE INC·Filed 2023·Application pending·0 cites
- 2274US11992528B2Compositions and methods for conjugating activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2021·Granted May 28, 2024·0 cites·20 claims
- 2372US2020031951A1Conjugated anti-cd38 antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2019·Application pending·0 cites
- 2472US2022306759A1Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2564US2023331841A1Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruptionCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 2664US2019111150A1Anti-cd71 activatable antibody drug conjugates and methods of use thereofABBVIE INC·Filed 2018·Application pending·0 cites
- 2763US2021145978A1Anti-cd71 activatable antibody drug conjugates and methods of use thereofABBVIE INC·Filed 2020·Application pending·0 cites
- 2859US2020002416A1C10rf32 antibodies, and uses thereof for treatment of cancerCOMPUGEN LTD·Filed 2019·Application pending·0 cites
- 2956US2017072067A1Compositions and methods for conjugating activatable antibodiesCYTOMX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3052US2019309072A1Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3145US2017233473A1C10rf32 antibodies, and uses thereof for treatment of cancerCOJOCARU GADY S·Filed 2017·Application pending·0 cites
- 3242US2024002348A1Quinolone compounds and process for preparation thereofCOUNCIL OF SCIENT AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN·Filed 2021·Application pending·0 cites
- 3333US12459893B2Indole-ynone mediated benzoannulation process for the preparation of carbazoles, carbazomycin A, calothrixin B and staurosporinoneCOUNCIL FOR SCIENT & INDUSTRIAL RESEARCH·Filed 2020·Granted Nov 4, 2025·0 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when Shweta Singh files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →